While the company is showing early signs of recovery and margin improvement, a high valuation means risks remain.

Humacyte markets Symvess for the treatment of extremity vascular trauma. Read why HUMA stock is a Sell but can see its ...

An experimental drug empowered by artificial intelligence to identify a novel therapeutic target for a severe lung disease ...